Vividion Therapeutics

Vividion Therapeutics is a company in San Diego, United States. It combines chemoproteomics and covalent chemistry to develop small molecule therapeutics aimed at previously undrugged drivers of disease, with the goal of bringing more disease-causing targets within reach of small molecule medicines. Its drug discovery engine has yielded multiple novel drug candidates that are being evaluated in clinical trials, and it is advancing a diversified pipeline of potential first-in-class therapeutics across oncology and immunology programs.

Vividion Therapeutics is a company in San Diego, United States. It combines the power of chemoproteomics and covalent chemistry to forge connections between precision therapeutics and previously undrugged drivers of disease, aiming to bring more disease-causing targets within the reach of small molecule therapeutics. Its drug discovery engine has yielded multiple novel drug candidates that are being evaluated in clinical trials. The company uses a covalent-first chemoproteomics approach to discover and develop new therapeutics that bind challenging-to-drug disease-causing protein targets, and reports having uncovered hundreds of druggable pockets on protein targets with validated biology and links to disease, as well as compounds that interact with these pockets in a highly selective manner. It states it has progressed multiple candidates from initial screening to clinical trials and has a deep pipeline of programs poised for future clinical entry. Aleksandra Rizo joined Vividion in 2022 as President and Head of Research and Development, and in 2023 was promoted to President and Chief Executive Officer and joined the Board of Directors.

Small molecule therapeutics developer using a covalent-first chemoproteomics approach to target previously undrugged disease-causing proteins.

• VVD-037

  A highly selective, first-in-class small molecule activator of KEAP1 that allosterically enhances the ability of this E3 ligase to degrade its natural cellular target, NRF2; in the oncology pipeline for solid tumors at Early Clinical (Phase 1).

• VVD-214

  A WRN inhibitor in the oncology pipeline for solid tumors with microsatellite instability.

• VVD-642

  A RAS-PIK3CA inhibitor in the oncology pipeline for solid tumors.

• 2021.05.04

  Reported2021.05.04

  Vividion appoints Christine Siu to its board[5]Vividion 任命 Christine Siu 为董事会成员biospace.com

  Vividion Therapeutics announced that Christine Siu had joined its board of directors.

• 2020.05.20

  Reported2020.05.20

  Roche and Vividion enter an exclusive worldwide option and license agreement[6]Roche与Vividion签订全球独家选择权及许可协议pharmatimes.com

  Roche signed an exclusive worldwide option and license agreement with Vividion Therapeutics for access to its proteomics screening platform and small molecule library and the option to license compounds arising from selected programmes.

Read more

1. 1Home — Vividion Therapeuticsvividion.com
2. 2About Us — Vividion Therapeuticsvividion.com
3. 3Science & Platform — Vividion Therapeuticsvividion.com
4. 4Pipeline & Programs — Vividion Therapeuticsvividion.com
5. 5Vividion 任命 Christine Siu 为董事会成员biospace.com
6. 6Roche与Vividion签订全球独家选择权及许可协议pharmatimes.com